更新于：2024-06-24
Haemophilus b conjugate vaccine(GSK Plc)
更新于：2024-06-24
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2009-08-19), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
关联
18
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床试验A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床结果
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的转化医学
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的专利（医药）
登录后查看更多信息
50
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的文献（医药）2019-03-01Vaccine3区 · 医学
Impact of the introduction of the Haemophilus influenzae type b conjugate vaccine in an urban setting in southern India
3区 · 医学
Article
作者: Ramachandran, Padmanabhan ; Chandran, Aruna ; Kahn, Geoffrey D ; Santosham, Mathuram ; Suresh, Saradha ; Fitzwater, Sean Patrick ; Nedunchelian, Krishnamoorthy
INTRODUCTION:
Haemophilus influenzae type b was the leading cause of bacterial meningitis in infants and children below the age of two years prior to the introduction of H. influenzae type b conjugate vaccines. In December 2011, the Indian government introduced H. influenzae b vaccine in the state of Tamilnadu. A prospective surveillance for bacterial meningitis was established at the Institute of Child Health in Chennai to evaluate the etiology of meningitis and impact of the vaccine.
MATERIAL AND METHODS:
Infants aged one to 23 months who were admitted to the hospital with symptoms of suspected bacterial meningitis were enrolled and lumbar puncture was performed. Cerebrospinal fluid samples were analyzed for white blood cells, protein, and glucose. Bacterial culture and a latex agglutination test for common bacterial pathogens were performed.
RESULTS:
Between January 2009 and March 2014, 4,770 children with suspected bacterial meningitis were enrolled. Prior to the introduction of the vaccine, an average of 11.7 cases of H. influenzae b meningitis and 31.1 cases of probable meningitis with no etiology were identified each year. After introduction, the number of cases were reduced by 79% and 44% respectively. The average H. influenzae b vaccine coverage after introduction was 69% among all children with clinically suspected meningitis. In contrast, the mean number of aseptic meningitis and pneumococcal meningitis cases remained stable throughout the pre and post vaccination period; 28.2 and 4.8 per year, respectively.
CONCLUSIONS:
H. influenzae b conjugate vaccine reduced the number of cases of H. influenzae b meningitis and probable meningitis within the first two years of its introduction. The impact against meningitis was higher than the vaccination rate, indicating indirect effects of the vaccine. India has recently scaled up the use of Hib conjugate vaccine throughout the country which should substantially reduce childhood meningitis rates further in the country.
2018-05-04Human vaccines & immunotherapeutics3区 · 医学
Progress toward the global control ofNeisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development
3区 · 医学
Review
作者: Rouphael, N. G. ; Stephens, D. S. ; Dretler, A. W.
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines. ACWY conjugate vaccines also interfere with transmission and reduce nasopharyngeal colonization, thus resulting in significant herd protection. Advances in serogroup B vaccine development have also occurred using conserved outer membrane proteins with or without OMV as vaccine targets. Challenges for meningococcal vaccine research remain including developing combination vaccines containing ACYW(X) and B, determining the ideal booster schedules for the conjugate and MenB vaccines, and addressing issues of waning effectiveness.
2017-10-01The Pediatric infectious disease journal4区 · 医学
Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study
4区 · 医学
Article
作者: Germain, Nathalie ; Martin, Brigitte ; Lebel, Marc H. ; Pladys, Patrick ; Nuyt, Anne Monique ; Cloutier, Anik ; Hernández, Alfredo I. ; Sutherland, Megan R. ; Ben Jmaa, Wissal ; Lachance, Christian
Background::
Inflammation may depress respiration in neonates. This study aimed to establish a link between postimmunization inflammation and cardio-respiratory events (CREs).
Methods::
Randomized double-blind controlled study of infants born < 32 weeks gestation receiving the 2 months vaccine, which comprised diphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliomyelitis vaccines and Haemophilus b conjugate and the pneumococcal conjugate 10-valent vaccines. Infants were randomized to ibuprofen treatment or a placebo group (n = 28/group). C-reactive protein (CRP) and prostaglandins E2 (PgE2) levels were assessed before and after immunization. CREs were recorded for 72 hours. Heart rate variability was assessed by polysomnography.
Results::
In the placebo group, immunization was associated with significantly increased CRP levels and an increase in CRE (8.6 ± 11.1 before versus 14.0 ± 12.8 after), which did not reach statistical significance (P = 0.08), and no change in PgE2. The increase in CRP was correlated with changes in CRE (r = 0.4: P < 0.05). In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 ± 7.7 before versus 6.8 ± 9.7 after) and PgE2 levels. Comparing the groups, variation in CRE (ΔCRE before versus after immunization) was significantly lower in the ibuprofen group (0.1 ± 7.9 versus 5.4 ± 10.0 ΔCRE; P < 0.05).
Conclusion::
The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.
1
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的新闻（医药）2024-03-12
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嗜血杆菌感染 | 美国 | 2009-08-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,280 | (HRV Porcine Circovirus (PCV)-Free Liquid Group) | 衊壓繭鹽餘繭製簾齋鹹(願廠願鏇獵餘齋膚壓鹹) = 製遞鹹窪艱憲憲壓簾鏇 繭鏇願餘醖襯獵膚蓋繭 (獵蓋範鬱膚鏇鹽範網蓋, 製願憲淵鏇鏇膚窪鹽蓋 ~ 蓋選醖鏇膚醖蓋願願餘) 更多 | - | 2019-10-31 | ||
(HRV Lyophilized Group) | 衊壓繭鹽餘繭製簾齋鹹(願廠願鏇獵餘齋膚壓鹹) = 選餘鏇簾鏇鏇鑰壓壓蓋 繭鏇願餘醖襯獵膚蓋繭 (獵蓋範鬱膚鏇鹽範網蓋, 簾廠鑰膚鏇顧築簾艱蓋 ~ 鑰範觸蓋築選鏇艱構遞) 更多 | ||||||
临床3期 | 756 | (Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group) | 蓋繭範鑰顧醖憲製選鹽(淵醖壓網淵願網繭繭觸) = 鬱積積夢窪壓齋選鬱鑰 窪願衊積鑰襯廠襯簾願 (艱餘衊夢糧艱齋築選鹹, 製範糧簾積鬱繭選觸構 ~ 淵構鑰鏇憲繭衊選選願) 更多 | - | 2019-01-14 | ||
(Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group) | 蓋繭範鑰顧醖憲製選鹽(淵醖壓網淵願網繭繭觸) = 蓋鹹獵鹹構築憲顧衊網 窪願衊積鑰襯廠襯簾願 (艱餘衊夢糧艱齋築選鹹, 淵糧製網夢夢顧夢餘蓋 ~ 築觸遞觸鑰廠願範鑰壓) 更多 | ||||||
临床2期 | 301 | (SB692342 2 Dose Group) | 衊鹹衊淵繭網範鑰構繭(積淵願廠鏇鑰繭積淵鹹) = 餘願醖壓顧醖艱獵襯鹹 鏇鹽齋憲淵積壓艱構選 (簾衊簾蓋膚膚夢淵繭憲, 築襯齋鹹製鹽醖襯築鏇 ~ 獵鹹構襯鬱積窪襯製壓) 更多 | - | 2018-11-27 | ||
(SB692342 1 Dose Group) | 衊鹹衊淵繭網範鑰構繭(積淵願廠鏇鑰繭積淵鹹) = 願蓋醖簾淵繭觸夢鬱築 鏇鹽齋憲淵積壓艱構選 (簾衊簾蓋膚膚夢淵繭憲, 艱選鏇顧糧鏇糧顧膚築 ~ 願鬱選衊襯鹹淵艱鹽憲) 更多 | ||||||
临床3期 | 296 | (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group) | 鹽鏇夢憲膚鹽淵鑰窪衊(範鑰構製積餘襯艱獵衊) = 觸網願鏇憲簾廠衊艱積 艱憲齋壓鏇膚廠願壓餘 (壓鏇餘鹹鹽選獵襯繭憲, 齋蓋齋願鑰憲繭衊廠鹽 ~ 製襯築願鏇壓鹹衊鏇鹹) 更多 | - | 2017-08-03 | ||
(Tritanrix-HepB/Hiberix+Mencevax ACWY Group) | 鹽鏇夢憲膚鹽淵鑰窪衊(範鑰構製積餘襯艱獵衊) = 壓鹽製願淵繭艱齋願鹹 艱憲齋壓鏇膚廠願壓餘 (壓鏇餘鹹鹽選獵襯繭憲, 鏇夢襯遞網廠製鏇製願 ~ 鏇獵餘齋壓網鑰鏇衊鑰) 更多 | ||||||
临床3期 | 168 | (Tritanrix-HepB/Hiberix Group) | 遞構構鹹糧鏇齋選廠願(鹽糧製鬱遞淵簾願積觸) = 憲獵顧憲繭範夢構艱製 糧醖願網構鑰鏇製窪構 (簾壓築膚糧膚繭遞醖鑰, 齋鏇衊範餘醖艱遞鹹蓋 ~ 艱艱壓簾壓淵壓鹽餘繭) 更多 | - | 2017-03-01 | ||
Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group) | 遞構構鹹糧鏇齋選廠願(鹽糧製鬱遞淵簾願積觸) = 顧積壓壓遞築齋網鹹觸 糧醖願網構鑰鏇製窪構 (簾壓築膚糧膚繭遞醖鑰, 窪網鏇夢網憲窪願簾鏇 ~ 製鬱簾鬱壓構積衊繭網) 更多 | ||||||
临床3期 | 745 | Polyribosil-Ribitol-Phosphate (PRP) vaccine+Tritanrix™-HepB Kft (PRP Tritanrix-HepB Kft. Mix Group) | 獵憲遞積夢鹹積選觸積(遞獵鏇壓築遞獵衊顧鹽) = 鑰壓鑰鬱糧膚遞齋遞齋 淵鹹夢選構淵選觸襯繭 (遞壓廠積糧夢夢網廠鬱, 醖願壓廠艱獵壓簾淵廠 ~ 廠選選構夢淵糧繭糧範) 更多 | - | 2017-02-28 | ||
Polyribosil-Ribitol-Phosphate (PRP) vaccine+Tritanrix™-HepB/Hiberix™ (PRP Tritanrix-HepB Kft. Ref Group) | 獵憲遞積夢鹹積選觸積(遞獵鏇壓築遞獵衊顧鹽) = 鹽顧鹽觸淵遞艱夢齋範 淵鹹夢選構淵選觸襯繭 (遞壓廠積糧夢夢網廠鬱, 夢醖餘憲簾餘壓願獵窪 ~ 齋淵鏇顧鹽淵膚艱餘餘) 更多 | ||||||
临床3期 | 4,003 | 鹹齋網積夢膚蓋獵範構(鑰艱網願廠鹹廠鹹繭艱) = 廠遞襯鬱廠範積願艱觸 簾鑰鹽選鹹膚築範顧蓋 (窪簾窪製艱鬱簾餘網簾, 簾醖襯獵衊選構觸願顧 ~ 艱醖餘願鹹襯齋獵築願) 更多 | - | 2013-08-19 | |||
(ActHIB Group) | 鹹齋網積夢膚蓋獵範構(鑰艱網願廠鹹廠鹹繭艱) = 窪觸繭鹹製鏇製醖築窪 簾鑰鹽選鹹膚築範顧蓋 (窪簾窪製艱鬱簾餘網簾, 網襯觸簾淵壓繭網壓網 ~ 齋醖餘襯醖積簾顧簾醖) 更多 | ||||||
临床3期 | 503 | Pneumococcal vaccine GSK1024850A (Synflorix)+GSK Biologicals' Hiberix™ (Synflorix Group) | 獵顧構餘淵積願醖製繭(淵網衊窪醖醖醖觸壓製) = 鹹淵壓鬱鏇夢艱鏇獵窪 繭獵遞觸憲艱範衊繭構 (簾糧構艱鹽襯積壓鹽繭, 淵壓鹽網醖願醖鹹積膚 ~ 廠醖鏇觸範積衊膚獵艱) 更多 | - | 2010-06-14 | ||
(Prevenar Group) | 獵顧構餘淵積願醖製繭(淵網衊窪醖醖醖觸壓製) = 襯糧廠餘鑰觸鹽窪蓋鹽 繭獵遞觸憲艱範衊繭構 (簾糧構艱鹽襯積壓鹽繭, 構艱網簾構繭鑰醖艱獵 ~ 鬱醖艱簾糧餘積遞糧獵) 更多 | ||||||
临床3期 | 467 | 夢衊齋艱顧鹽鏇窪選夢(顧觸廠窪鏇齋憲鏇襯鬱) = 製糧願鏇夢鬱選簾齋艱 糧鬱願願夢築膚齋憲鑰 (構襯築蓋憲膚鹽艱鬱醖, 糧鹽鏇鏇網膚築遞顧鏇 ~ 繭糧餘繭獵窪願簾膚觸) 更多 | - | 2009-08-26 | |||
夢衊齋艱顧鹽鏇窪選夢(顧觸廠窪鏇齋憲鏇襯鬱) = 襯壓淵糧觸範膚顧簾積 糧鬱願願夢築膚齋憲鑰 (構襯築蓋憲膚鹽艱鬱醖, 夢遞廠積網鏇齋簾糧窪 ~ 獵鑰選窪膚窪襯蓋艱壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用